Merck Immunotherapy Drug Notches Another FDA Win in Lung Cancer

The FDA has approved use of a Merck drug in combination with chemotherapy as a first-line treatment for the most common type of lung cancer. The FDA approval for (NYSE: [[ticker:MRK]]) pembrozlizumab (Keytruda) to treat metastatic nonsquamous non-small cell lung cancer widens the use of the immunotherapy. Last year, the FDA approved it for lung … Continue reading “Merck Immunotherapy Drug Notches Another FDA Win in Lung Cancer”

Structural Launches with Software to Unleash Employee Productivity

Structural is on a mission to unlock workplace data to help optimize the way offices function. The employee-management software startup—based in Indianapolis and St. Paul, MN, and backed by High Alpha—has set out to apply analytics and other technologies to produce workforce insights that were previously hiding in the raw data of human-resources files. Until … Continue reading “Structural Launches with Software to Unleash Employee Productivity”

Senate Vote Confirms Scott Gottlieb for FDA Commissioner

Scott Gottlieb will be the new FDA commissioner. The U.S. Senate voted 57 to 42 on Tuesday to confirm Gottlieb, a physician and venture capitalist, to lead the regulatory agency. He succeeds former FDA commissioner Robert Califf, who stepped down in January after President Donald Trump took office. Gottlieb is already familiar with the agency … Continue reading “Senate Vote Confirms Scott Gottlieb for FDA Commissioner”

Sonam Technologies Wants to Reduce Risk of Playground Brain Injuries

In the past few years, we’ve heard a lot about the dangers of traumatic brain injuries. While we usually hear about these injuries in the context of high-impact sports like football or boxing, traumatic brain injuries are also a risk for kids that fall off playground equipment. These kinds of accidents are more prevalent and … Continue reading “Sonam Technologies Wants to Reduce Risk of Playground Brain Injuries”

Bio Roundup: NIH Precision Boost, AHCA to Senate, New Drugs & More

Two dramatic healthcare stories played out this week. First, to the jubilation of the nation’s science community, Congress proposed to boost National Institutes of Health funding, not slash it as the Trump administration had outlined. Then the patchwork revival of the GOP’s healthcare plan, despite being panned by nearly every major medical group in the … Continue reading “Bio Roundup: NIH Precision Boost, AHCA to Senate, New Drugs & More”

TechPoint’s Mira Awards: MOBI Wins Company of the Year

TechPoint, the organization dedicated to growing Indiana’s tech ecosystem, held its annual Mira Awards gala in front of a packed house on Saturday. Meant to recognize the success and innovation of the state’s tech companies, entrepreneurs, educators, and other leaders, the Miras have been awarded for the past 18 years. From the 180 nominating applications … Continue reading “TechPoint’s Mira Awards: MOBI Wins Company of the Year”

VC Confidence Holds Steady in Quarterly Survey, But Reasons Change

In a survey of 29 Silicon Valley venture capitalists in December, the VCs mulled whether President-elect Donald Trump would buoy up their investment prospects with lower corporate taxes and government regulations, or worsen conditions by heightening global political instability and raising the risk of a major military conflict or economic downturn. That Q4 2016 edition … Continue reading “VC Confidence Holds Steady in Quarterly Survey, But Reasons Change”

If Budget Holds, NIH Precision Study Could Be Flush As Volunteers Arrive

Until this week, many U.S. government science agencies and programs seemed destined for a big haircut, plus the loss of a limb or two. That included the Precision Medicine Initiative, an ambitious long-term study with the goal of recruiting 1 million Americans to volunteer health data. But in staving off a government shutdown, Congress pushed … Continue reading “If Budget Holds, NIH Precision Study Could Be Flush As Volunteers Arrive”

Analysis: Trump’s First 100 Days Through the Tech Industry Lens

Donald Trump spent his 100th day in office in ways that would appeal to his working class base—holding a campaign-style rally in Harrisburg, PA, where he confirmed his campaign commitment to controlling immigration. Trump also signed an executive order to create a White House office of trade and manufacturing policy, which aims to protect American … Continue reading “Analysis: Trump’s First 100 Days Through the Tech Industry Lens”

Angie’s List, Grown in Indiana, Merging with Colorado’s HomeAdvisor

Two days after Angie Hicks, the co-founder and chief marketing officer of home services website Angie’s List, won an award for being a trailblazer in Indiana’s technology sector, her company announced it is heading down a new path. Angie’s List has agreed to be sold to Internet giant IAC, which will merge Hicks’s firm with … Continue reading “Angie’s List, Grown in Indiana, Merging with Colorado’s HomeAdvisor”

A.I.’s Role In Agriculture Comes Into Focus With Imaging Analysis

The imaging technologies scanning farms today trace their roots to the space race. In 1965, the U.S. Geological Survey proposed using satellites to observe the planet. Seven years later, NASA launched Landsat 1. Among that satellite’s accomplishments: an estimate of the corn and soybean acreage stretching from Iowa to Indiana. The eighth version of Landsat … Continue reading “A.I.’s Role In Agriculture Comes Into Focus With Imaging Analysis”

The State of Cybersecurity Insurance Today

Cyber incidents are considered the No. 1 emerging risk for enterprises long-term. No surprise, then, that cybersecurity insurance policy premiums are approaching $2.75 billion a year. Some experts believe this figure will grow to roughly $20 billion by 2025. For scores of insurance companies cashing in on the booming corporate cybersecurity insurance market, it’s a … Continue reading “The State of Cybersecurity Insurance Today”

Zymeworks Bags $58M in IPO to Bankroll Cancer Drug Trials

Zymeworks is the latest biotech to go public, raising $58.5 million through a stock offering that the company says will finance early stage clinical trials for its two lead cancer drug candidates. Vancouver, BC-based Zymeworks sold 4.5 million shares at $13 apiece, coming in at the low end of the $13 to $16 per range … Continue reading “Zymeworks Bags $58M in IPO to Bankroll Cancer Drug Trials”

Radius Nabs FDA OK For New Bone Drug With Rival Amgen Close Behind

At least one new treatment is on the way for osteoperosis patients, and possibly two before the end of the summer. Radius Health on Friday won FDA approval of an osteoperosis drug that, like a rival treatment from Eli Lilly, can help build up the strength of bones rather than just prevent them from becoming … Continue reading “Radius Nabs FDA OK For New Bone Drug With Rival Amgen Close Behind”

Bio Roundup: Trumpcare Flails, Spinraza Sales, Batten OK & More

To judge the first 100 days of a new administration is, as many pundits have pointed out, an odd vestige of history, more convenient than significant. Which is why we’ll start this week’s roundup with our 99-day evaluation of the Trump administration—at least when it comes to healthcare and the life sciences. In healthcare, nothing … Continue reading “Bio Roundup: Trumpcare Flails, Spinraza Sales, Batten OK & More”

TCC Plans to Expand Offerings After Acquiring Vertex, Triple Impact

TCC Software Solutions, an Indianapolis-based IT cloud-hosting company, announced this week that it has acquired two businesses: Vertex Solutions Group and Triple Impact. Financial terms of the deal were not disclosed. Jim Pangallo, principal partner at TCC, says the two companies came to TCC’s attention through Harborside Advisors, a Florida firm that arranged the acquisition. … Continue reading “TCC Plans to Expand Offerings After Acquiring Vertex, Triple Impact”

Hacking Back: Agari Turns the Tables on Next-Gen E-mail Scammers

What would happen if a total stranger with a poor command of English asked the payroll manager of an American corporation to send him the Internal Revenue Service Form W-2’s for the company’s entire staff? Answer: Some payroll managers would obligingly send the stranger a PDF of all the forms, containing the names, Social Security … Continue reading “Hacking Back: Agari Turns the Tables on Next-Gen E-mail Scammers”

Gottlieb’s FDA Nomination Gets Committee Nod, Advances to Senate

Scott Gottlieb’s nomination to the top post of the FDA is on its way to the full U.S. Senate. The Senate Health, Education, Labor & Pensions Committee voted 14-9 on Thursday to approve Gottlieb’s nomination to become FDA commissioner. All of the Republicans on the committee voted for Gottlieb, along with two Democrats, Sen. Sheldon … Continue reading “Gottlieb’s FDA Nomination Gets Committee Nod, Advances to Senate”

After Steady Growth, Greenlight.guru Plans New Office, More Hires

The Indianapolis-based startup Greenlight.guru, maker of quality management software for organizations in the medical device industry, plans to invest $651,022 in a new, 7,200-square-foot office at Union 525, a tech hub in the city’s downtown. The new office is part of an expansion plan now underway, and the company expects to create up to 120 … Continue reading “After Steady Growth, Greenlight.guru Plans New Office, More Hires”

Becton Dickinson Aims Beyond Diabetes with $24B Bard Deal

In a medical technology merger with implications for the healthcare sector in the United States and beyond, Becton Dickinson is acquiring C.R. Bard for $24 billion to tap into the growing markets for products used in treating vascular conditions and cancer. Under the deal announced Sunday, Franklin Lakes, NJ-based Becton Dickinson (NYSE: [[ticker:BD]]) will pay … Continue reading “Becton Dickinson Aims Beyond Diabetes with $24B Bard Deal”

Bio Roundup: Spinraza Woes, Science March, Baseline Launch & More

Rumblings of a new Obamacare replacement surfaced this week, while scientists and their supporters prepared for Saturday’s—a.k.a. Earth Day’s—nationwide Marches for Science. Our own reporting focused this week on the fallout from high drug prices, with a look at the frustration of families whose children have had trouble gaining access to the first drug ever … Continue reading “Bio Roundup: Spinraza Woes, Science March, Baseline Launch & More”

After 3-Year Partnership, DePuy Acquires TRS Scaffolding Technology

In 2014, Plymouth, MI-based biotech startup Tissue Regeneration Systems (TRS) began collaborating with DePuy Synthes Products, a company under the Johnson & Johnson umbrella making orthopedic products, such as the devices used in joint replacements. This week, DePuy formalized that relationship with the announcement that it has acquired TRS’s FDA-approved, 3D-printed scaffolding technology that enables … Continue reading “After 3-Year Partnership, DePuy Acquires TRS Scaffolding Technology”

Request Your Invitation to Xconomy’s Elite Napa Summit June 8-9

  Nobel Laureate David Baltimore. Microbiome AND supercomputer pioneer Larry Smarr. Intellectual Ventures’ Nathan Myhrvold. Nicole Glaros of Techstars. These are just a few of the visionary speakers who will be headlining Xconomy’s sixth annual Napa Summit. And if you act fast to request your invitation to this special event, you can join them and … Continue reading “Request Your Invitation to Xconomy’s Elite Napa Summit June 8-9”

“Our Son’s Fate”: Parents Fighting for Kids’ Spine Drug Eye New Data

Melissa Marotta pulled no punches to get her three-year-old son C.J., who has the genetic disease spinal muscular atrophy, access to nusinersen (Spinraza), the first approved drug for his condition. For months, she couldn’t schedule a treatment date at Columbia University Medical Center/New York-Presbyterian Morgan Stanley Children’s Hospital, and for much of that time, she … Continue reading ““Our Son’s Fate”: Parents Fighting for Kids’ Spine Drug Eye New Data”

Trump Executive Order Adds Uncertainty to Tech Visa Program

Is the U.S. high-skilled visa program, known as H-1B, an essential contributor to the innovation economy or a way for companies to replace American IT workers with immigrants at lower salaries? It’s a debate as old as the program itself, which began in 1990. The Trump administration on Tuesday joined the fray with a long-anticipated … Continue reading “Trump Executive Order Adds Uncertainty to Tech Visa Program”

The Xconomy Roadmap: Top 15 Innovation Areas to Watch (and Disrupt)

It is a time of great transitions in the technology and business world. Key advances in areas like machine intelligence, agriculture, and healthcare seem poised to transform society—and everyday life. But it can be hard to keep up with the latest news in fields as disparate as cybersecurity, food tech, and cancer therapeutics—let alone understand … Continue reading “The Xconomy Roadmap: Top 15 Innovation Areas to Watch (and Disrupt)”

Want to Communicate Your Science? First, Step Back

Think for a moment about the words and phrases that life science researchers and executives use on a daily basis. I’m talking about the seemingly simple phrases like “investigational drug,” “novel target,” “immunotherapy,” “clinical trial,” “in vitro,” and “therapeutic window.” There are hundreds more. Those of us who work in life sciences are comfortable with … Continue reading “Want to Communicate Your Science? First, Step Back”

Angie’s List Co-Founder Talks Diversity and Building Tech Ecosystems

It’s a bit ironic that Angie Hicks, co-founder and chief marketing officer of Indianapolis-based Angie’s List, didn’t originally plan to be an entrepreneur. Before she helped found the business-listings company 22 years ago, she was an intern at a venture capital firm with plans of becoming a consultant because, she says, that’s what economics majors … Continue reading “Angie’s List Co-Founder Talks Diversity and Building Tech Ecosystems”

MIT Entrepreneurship Guru Bill Aulet Coming to IN on April 27 and 28!

Xconomy is partnering with two great organizations to bring Bill Aulet, managing director of the Martin Trust Center for MIT Entrepreneurship and senior lecturer at the MIT Sloan School of Management, to Indiana to share his knowledge about starting new enterprises. First up for Aulet is an afternoon meetup at Launch Fishers on Thursday, April … Continue reading “MIT Entrepreneurship Guru Bill Aulet Coming to IN on April 27 and 28!”

Cancer Drugmaker G1 Therapeutics Makes IPO Pitch To Wall Street

Pharmaceutical giants Pfizer and Novartis were first to gain regulatory approval with drugs that block a pair of enzymes important to tumor growth in breast cancer. Clinical-stage biotech G1 Therapeutics has a different approach to those same enzymes and will ask investors in the public markets to get on board. Research Triangle Park, NC-based G1 … Continue reading “Cancer Drugmaker G1 Therapeutics Makes IPO Pitch To Wall Street”

FDA Nixes Lilly, Incyte RA Drug, Seeks More Dosing and Safety Data

[Updated 4/14/17, 2:51 pm. See below.] In a surprise decision, the FDA has declined to approve an experimental rheumatoid arthritis (RA) treatment from Eli Lilly and Incyte, dealing a setback to a drug that is already approved in Europe and was expected to pass muster with U.S. regulators. Eli Lilly (NYSE: [[ticker:LLY]]) and Incyte (NASDAQ: … Continue reading “FDA Nixes Lilly, Incyte RA Drug, Seeks More Dosing and Safety Data”

Why Bots Aren’t the Real AI Disruption: The Quiet Rise of Headless AI

Editor’s note: This piece was originally posted on Textio’s company blog. “Hey Siri, how’s the weather today?” “OK Google, remind me to pay the power bill.” “Alexa, tell me a joke!” Bots are eating the world. Whether you are an enterprising app developer building the essential software to bring a virtual Taylor Swift into your … Continue reading “Why Bots Aren’t the Real AI Disruption: The Quiet Rise of Headless AI”

Bio Roundup: CRISPR Appeal, Bristol Deals, Stock Pumping & More

It may have been a short holiday week, but there was plenty of news on the CRISPR front. In the ongoing battle for rights to the landmark gene editing technology, the faction led by the University of California appealed the U.S. decision in favor of the Broad Institute. Elsewhere, Bristol-Myers Squibb flipped assets, a top … Continue reading “Bio Roundup: CRISPR Appeal, Bristol Deals, Stock Pumping & More”

Plymouth Growth Partners Snags MIRA Award for Investor of the Year

A few years ago, when Ann Arbor, MI-based Plymouth Growth Partners was searching for new places to invest the $61 million in its third venture fund, the firm decided to look outside the Great Lakes State. “We were pretty heavily invested in Chicago and Michigan already,” recalls Jeff Barry, a partner at the firm formerly … Continue reading “Plymouth Growth Partners Snags MIRA Award for Investor of the Year”

Rippleshot Uses Big Data Tools to Mitigate Credit Card Fraud

A company founded by an Indiana University graduate to fight payment-card fraud with data analytics, statistical modeling, and machine learning is now backed by the school’s Innovate Indiana Fund. Part of a $2.6 million investment round, the funding will help Chicago-based Rippleshot launch a new product later this year aimed at stopping criminals from scamming … Continue reading “Rippleshot Uses Big Data Tools to Mitigate Credit Card Fraud”

The Otonomy Story and the Human Impact of Innovation

[Editor’s note: Jay Lichter will discuss his personal odyssey in drug development on April 19 at The Xconomy Forum on the Human Impact of Innovation. Online registration is here.] I am a pharmaceutical scientist and a biotech venture capitalist. I start companies that are focused on creating new drugs. So when my doctor told me … Continue reading “The Otonomy Story and the Human Impact of Innovation”

Calling All Coders: Civic Hackathon Seeks to Harness IoT Tech

For most of its 200-year existence, Indiana’s economy has depended on three industries: manufacturing, logistics, and agriculture. Bill Soards, president of AT&T Indiana, says all of these sectors are “huge consumers” of Internet of Things technologies. Later this month, his company is hosting a civic hackathon in order to convene teams and get to work … Continue reading “Calling All Coders: Civic Hackathon Seeks to Harness IoT Tech”

Bio Roundup: Gottlieb Talks Vax, Acorda’s Axe, Adams, 23andMe & More

In the nation’s capital, healthcare and life sciences were on center stage. Or stages, actually. On Capitol Hill, FDA commissioner nominee Scott Gottlieb, the drug industry’s favorite pick, told senators his extensive industry ties wouldn’t cloud his judgment or create conflicts. At a downtown convention center, Joe Biden slammed the Trump administration’s budget-cutting plans. And … Continue reading “Bio Roundup: Gottlieb Talks Vax, Acorda’s Axe, Adams, 23andMe & More”

AACR Review: Biden Fired Up, Incyte Doubles Up, BMS Up And Down

The American Association for Cancer Research held its annual meeting this week in Washington, DC, a convenient venue for former Vice President Joe Biden to deliver a broadside against the Trump administration’s proposed budget cuts in science funding. For Biden, it’s personal. In the final year of the Obama administration, he championed a push for … Continue reading “AACR Review: Biden Fired Up, Incyte Doubles Up, BMS Up And Down”

Some Cause for Optimism in Hired’s Research on Gender Wage Gap

Amid the ongoing conversation about gender discrimination in the tech industry, and recent sexual harassment claims against some of its biggest names, here’s some sort-of good news about women in tech: When companies make job offers to both men and women, women receive lower salary offers 63 percent of the time for the same job, … Continue reading “Some Cause for Optimism in Hired’s Research on Gender Wage Gap”

FDA Nominee Scott Gottlieb To Anti-Vaccine Crowd: Get Over It

In what passes for a short hearing these days in Washington, DC, the Trump White House’s pick to run the Food and Drug Administration, Scott Gottlieb, spent less than three hours fielding questions from a Senate committee Wednesday morning. Amid predictable splits between Republican praise for his past industry experience and Democrat fire over potential … Continue reading “FDA Nominee Scott Gottlieb To Anti-Vaccine Crowd: Get Over It”

Slowdown Continues in First-Quarter VC Funding—and Top 10 Deals

Is a caution flag flying? While U.S. venture firms refueled last year by raising a near-record $51.6 billion, they also eased off the throttle in terms of their investment activity during the first quarter of 2017, according to data released today by Seattle-based PitchBook and the National Venture Capital Association (NVCA). According to the latest … Continue reading “Slowdown Continues in First-Quarter VC Funding—and Top 10 Deals”

Curvo Labs Aims to Help Hospitals Make Better Purchasing Decisions

Throughout his career working in the hospital supply chain, Curvo Labs CEO Andy Perry has seen a lot of changes. In the past decade, in particular, the rise of value-based reimbursement policies and new technologies have altered the way hospitals make purchases. In the past, it was up to the sales people at innovative medical … Continue reading “Curvo Labs Aims to Help Hospitals Make Better Purchasing Decisions”

How Battling New Epidemics Helps Fight Age-Old Killers

Washington state has reported nearly 300 cases of mumps this winter and experts predict this may be the state’s worst flu season in years, a stark reminder of how dangerous even familiar viruses can be. While the Ebola and Zika outbreaks have dominated the headlines in recent years, they are part of a paradigm we … Continue reading “How Battling New Epidemics Helps Fight Age-Old Killers”

Bio Roundup: New Drug Bonanza, Vertex’s Triple Play, CAR-T Race & More

As far as singular weeks go for biotech, this was a big one. Three highly anticipated drugs were approved. One is the first injectable medication for eczema. Another might help fend off the recurrence of ovarian cancer. And a third offers hope for people with severe forms of multiple sclerosis. Another drug, a new combination … Continue reading “Bio Roundup: New Drug Bonanza, Vertex’s Triple Play, CAR-T Race & More”

Fuzic Combines Music and On-Demand Marketing to Engage Customers

Before Brent Oakley co-founded Fuzic, an Indianapolis-based marketing technology startup, he owned carwashes. He wanted to make his customers happy, so he installed cafes in his carwashes, hoping that he’d be able to chat with his patrons while they sipped beverages and learn more about what they wanted out of a carwash. When that didn’t … Continue reading “Fuzic Combines Music and On-Demand Marketing to Engage Customers”

IBRI, Dow Agrosciences, Lilly Partner on Molecular Safety Database 

The Indiana Biosciences Research Institute (IBRI), a nonprofit, industry-led life sciences research institute focused on targeting cardio-metabolic diseases, diabetes and poor nutrition, has a new collaborative project underway. The IBRI is teaming up with Eli Lilly and Dow AgroSciences to create a shared data platform that assesses the potential effects different molecules have on human … Continue reading “IBRI, Dow Agrosciences, Lilly Partner on Molecular Safety Database “

Eli Lilly Reveals $850M Capital Spending Plan for Indiana and Beyond

Eli Lilly plans to pour more than more than $850 million into its research laboratories and manufacturing facilities across the country—a capital investment spree that includes a multi-million dollar expansion of a site that makes the delivery device for a top-selling diabetes drug. Indianapolis-based Eli Lilly (NYSE: [[ticker:LLY]]) unveiled the plans with government officials this … Continue reading “Eli Lilly Reveals $850M Capital Spending Plan for Indiana and Beyond”